MedTrace Logo

A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC

NCT02321293 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-09-02

No results posted yet for this study

Summary

The purpose of this study is is to assess the safety and tolerability of curcumin in combination with EGFR-TKIs in selected patients with advanced non-resectable mutant EGFR NSCLC.

Conditions

Interventions

DIETARY_SUPPLEMENT

CurcuVIVA™

80 mg PO daily for 8 weeks with an option to reduce the dose based on individual tolerability

DRUG

Tyrosine Kinase Inhibitor gefitinib (Iressa)

250 mg PO daily until progression

DRUG

Tyrosine Kinase Inhibitor erlotinib (Tarceva)

150 mg PO daily until progression

Sponsors & Collaborators

  • Jewish General Hospital

    collaborator OTHER

  • Lady Davis Institute

    lead OTHER

Principal Investigators

  • Victor Cohen, MD · Lady Davis Institute

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-08-31
Completion
2016-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02321293 on ClinicalTrials.gov